YU54401A - Primena derivata 4-h-1-benzopiran-4-ona kao inhibitora preteranog razmnožavanja ćelija glatkih mišića - Google Patents
Primena derivata 4-h-1-benzopiran-4-ona kao inhibitora preteranog razmnožavanja ćelija glatkih mišićaInfo
- Publication number
- YU54401A YU54401A YU54401A YUP54401A YU54401A YU 54401 A YU54401 A YU 54401A YU 54401 A YU54401 A YU 54401A YU P54401 A YUP54401 A YU P54401A YU 54401 A YU54401 A YU 54401A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- smc
- smooth muscle
- flavopiridol
- proliferation
- dependent kinase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 title abstract 3
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 150000004777 chromones Chemical class 0.000 title abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 6
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 abstract 4
- 229950010817 alvocidib Drugs 0.000 abstract 4
- 239000004471 Glycine Substances 0.000 abstract 3
- 230000001419 dependent effect Effects 0.000 abstract 3
- 230000035755 proliferation Effects 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 230000022131 cell cycle Effects 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 208000024248 Vascular System injury Diseases 0.000 abstract 1
- 208000012339 Vascular injury Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 210000002460 smooth muscle Anatomy 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Proliferacija ćelija glatkih mišića (SMC) je kritičan deo u formiranju zadebljanog sloja u arterijama kod povrede krvnih sudova. Ihibicija ćelijskog ciklusa gen-transter tehnikama može blokirati proliferaciju SMC i formiranje ozleda kod mnogih životinjskih modela. Flavopiridol je nedavno dobijen i moćan je inhibitor glicin zavisne kinaze. Ispitivali smo delovanje flavopiridola, kao inhibitora ćelija glatkih mišića (SMC) kod vaskularnih oboljenja, nedavno dobijenog inhibitora glicin zavisne kinaze na rast SMC in vitro. Flavopiridol (75 nmol/I/L) snažno je blokirao proliferaciju SMC, delovanje koje je povezano sa smanjenjem aktivnosti glicin zavisne kinaze i ekspresije gena povezane sa ćelijskim ciklusom. Farmaceutski preparati Flavopiridol-a mogu biti snažna terapeutska sredstva za lečenje ozleda krvnih sudova kod kojih se javlja velika količina SMC. Male doze farmaceutskih preparata derivata 4-H-1-benzopiran-4-ona mogu da inhibiraju proliferaciju glatkih mišića.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24338099A | 1999-02-01 | 1999-02-01 | |
US09/468,665 US6399633B1 (en) | 1999-02-01 | 1999-12-21 | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
Publications (2)
Publication Number | Publication Date |
---|---|
YU54401A true YU54401A (sh) | 2004-05-12 |
RS50242B RS50242B (sr) | 2009-07-15 |
Family
ID=22918541
Country Status (38)
Country | Link |
---|---|
US (1) | US6399633B1 (sh) |
EP (1) | EP1150746B1 (sh) |
JP (1) | JP4755759B2 (sh) |
KR (1) | KR100793047B1 (sh) |
CN (1) | CN1219556C (sh) |
AP (1) | AP1469A (sh) |
AR (1) | AR042569A1 (sh) |
AT (1) | ATE275428T1 (sh) |
AU (1) | AU777368B2 (sh) |
BG (1) | BG65151B1 (sh) |
BR (1) | BR0007911A (sh) |
CA (1) | CA2360668C (sh) |
CR (1) | CR6448A (sh) |
CZ (1) | CZ300395B6 (sh) |
DE (1) | DE60013555T2 (sh) |
DK (1) | DK1150746T3 (sh) |
EA (1) | EA004786B1 (sh) |
EE (1) | EE04851B1 (sh) |
ES (1) | ES2226792T3 (sh) |
HK (1) | HK1042445B (sh) |
HR (1) | HRP20010521A2 (sh) |
HU (1) | HU229263B1 (sh) |
ID (1) | ID30180A (sh) |
IL (1) | IL144668A (sh) |
ME (1) | MEP10508A (sh) |
NO (1) | NO330512B1 (sh) |
NZ (1) | NZ512822A (sh) |
OA (1) | OA11755A (sh) |
PL (1) | PL197693B1 (sh) |
PT (1) | PT1150746E (sh) |
RS (1) | RS50242B (sh) |
SI (1) | SI1150746T1 (sh) |
SK (1) | SK286747B6 (sh) |
TR (1) | TR200102223T2 (sh) |
TW (1) | TWI273907B (sh) |
UA (1) | UA73110C2 (sh) |
WO (1) | WO2000044362A2 (sh) |
ZA (1) | ZA200105596B (sh) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0102480D0 (en) * | 2001-01-31 | 2001-03-14 | Cyclacel Ltd | Marker |
BR0309278A (pt) * | 2002-04-17 | 2005-04-26 | Cytokinetics Inc | Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US20040106647A1 (en) * | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
US20040082613A1 (en) * | 2002-06-28 | 2004-04-29 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
US20040265315A1 (en) * | 2002-09-05 | 2004-12-30 | Christine Dingivan | Methods of preventing or treating T cell malignancies by administering CD2 antagonists |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
KR20120035234A (ko) | 2003-04-11 | 2012-04-13 | 메디뮨 엘엘씨 | 재조합 il?9 항체 및 그의 용도 |
US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
CA2536238C (en) | 2003-08-18 | 2015-04-07 | Medimmune, Inc. | Humanization of antibodies |
CA2585717A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
AU2006227377B2 (en) | 2005-03-18 | 2013-01-31 | Medimmune, Llc | Framework-shuffling of antibodies |
KR20080025174A (ko) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
WO2007010342A1 (en) * | 2005-07-15 | 2007-01-25 | Sahajanand Biotech Private Limited | Implantable medical devices comprising a flavonoid or derivative thereof for prevention of restenosis |
JP2008255008A (ja) * | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
KR101431279B1 (ko) * | 2005-07-29 | 2014-08-20 | 리스버로직스 코퍼레이션 | 복합 질환의 예방 및 치료용 약학적 조성물 및 삽입가능한의료 장치에 의한 이의 전달 |
MX2009002151A (es) | 2006-08-28 | 2009-07-03 | Kirin Pharma Kk | Anticuerpos monoclonales humanos especificos para light humano antagonistas. |
PL2118074T3 (pl) | 2007-02-01 | 2014-06-30 | Resverlogix Corp | Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego |
EP2077859A4 (en) | 2007-03-30 | 2010-11-24 | Medimmune Llc | ANTIBODY FORMULATION |
NZ586440A (en) | 2008-06-26 | 2011-07-29 | Resverlogix Corp | Methods of preparing quinazolinone derivatives |
ES2463097T3 (es) | 2009-01-08 | 2014-05-27 | Resverlogix Corp. | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
US9238640B2 (en) | 2009-03-18 | 2016-01-19 | Resverlogix Corp. | Anti-inflammatory agents |
NZ596117A (en) | 2009-04-22 | 2014-10-31 | Resverlogix Corp | Novel anti-inflammatory agents |
EP2593099A1 (en) | 2010-07-12 | 2013-05-22 | DKFZ Deutsches Krebsforschungszentrum | Wogonin for the prevention and therapy of cardiac hypertrophy |
WO2012103165A2 (en) | 2011-01-26 | 2012-08-02 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
HUE044986T2 (hu) | 2011-11-01 | 2019-11-28 | Resverlogix Corp | Orális, azonnali felszabadulású készítmények szubsztituált kinazolinonokhoz |
NZ630363A (en) | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
SG11201502757QA (en) | 2012-10-09 | 2015-05-28 | Igenica Biotherapeutics Inc | Anti-c16orf54 antibodies and methods of use thereof |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
KR20150096794A (ko) | 2012-12-21 | 2015-08-25 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물 |
US10100123B2 (en) | 2013-06-06 | 2018-10-16 | Pierre Fabre Medicament | Anti-C10orf54 antibodies and uses thereof |
KR20160054501A (ko) | 2013-08-26 | 2016-05-16 | 맵백스 테라퓨틱스, 인코포레이티드 | 시알릴-루이스 a에 대한 사람 항체 코드화 핵산 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
WO2015187811A2 (en) | 2014-06-04 | 2015-12-10 | MabVax Therapeutics, Inc. | Human monoclonal antibodies to ganglioside gd2 |
ES2834739T3 (es) | 2014-12-11 | 2021-06-18 | Pf Medicament | Anticuerpos anti-C10orf54 y utilizaciones de los mismos |
PL3265123T3 (pl) | 2015-03-03 | 2023-03-13 | Kymab Limited | Przeciwciała, zastosowania i sposoby |
CN114984016A (zh) | 2015-03-13 | 2022-09-02 | 雷斯韦洛吉克斯公司 | 用于治疗补体相关疾病之组合物及治疗方法 |
AU2016252609B2 (en) | 2015-04-20 | 2022-06-30 | Sumitomo Pharma Oncology, Inc. | Predicting response to alvocidib by mitochondrial profiling |
CN107849073B (zh) | 2015-05-18 | 2020-04-03 | 特雷罗药物股份有限公司 | 具有增加的生物利用度的阿伏西地前药 |
KR20180034538A (ko) | 2015-08-03 | 2018-04-04 | 톨레로 파마수티컬스, 인크. | 암의 치료를 위한 병행 요법 |
CN114470194A (zh) | 2015-12-02 | 2022-05-13 | 斯特库伯株式会社 | 与btn1a1免疫特异性结合的抗体和分子及其治疗用途 |
CN108925136B (zh) | 2015-12-02 | 2022-02-01 | 斯特赛恩斯公司 | 特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体 |
EP3503923B1 (en) | 2016-08-23 | 2023-10-04 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
AU2018234903B2 (en) | 2017-03-16 | 2024-02-08 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
AU2018277838A1 (en) | 2017-05-31 | 2019-12-19 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof |
US20200131266A1 (en) | 2017-05-31 | 2020-04-30 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
JP2020522562A (ja) | 2017-06-06 | 2020-07-30 | ストキューブ アンド シーオー., インコーポレイテッド | Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法 |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
WO2019073069A1 (en) | 2017-10-13 | 2019-04-18 | Boehringer Ingelheim International Gmbh | HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN) |
MX2021000786A (es) | 2018-07-20 | 2021-06-15 | Pf Medicament | Receptor para supresor de ig del dominio v de activación de células t (vista). |
US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
CN113559244B (zh) * | 2021-08-02 | 2023-12-26 | 华中科技大学同济医学院附属协和医院 | Ctrp13脂肪因子的新用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN164232B (sh) * | 1986-04-11 | 1989-02-04 | Hoechst India | |
US5284856A (en) * | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
US5908934A (en) | 1996-09-26 | 1999-06-01 | Bristol-Myers Squibb Company | Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs |
AU749750B2 (en) | 1997-02-05 | 2002-07-04 | Warner-Lambert Company | Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
-
1999
- 1999-12-21 US US09/468,665 patent/US6399633B1/en not_active Expired - Fee Related
-
2000
- 2000-01-18 UA UA2001075481A patent/UA73110C2/uk unknown
- 2000-01-18 EE EEP200100385A patent/EE04851B1/xx not_active IP Right Cessation
- 2000-01-18 TR TR2001/02223T patent/TR200102223T2/xx unknown
- 2000-01-18 CN CNB008032513A patent/CN1219556C/zh not_active Expired - Fee Related
- 2000-01-18 JP JP2000595666A patent/JP4755759B2/ja not_active Expired - Fee Related
- 2000-01-18 OA OA1200100196A patent/OA11755A/en unknown
- 2000-01-18 AT AT00909918T patent/ATE275428T1/de active
- 2000-01-18 CA CA002360668A patent/CA2360668C/en not_active Expired - Fee Related
- 2000-01-18 WO PCT/US2000/001104 patent/WO2000044362A2/en active IP Right Grant
- 2000-01-18 DK DK00909918T patent/DK1150746T3/da active
- 2000-01-18 HU HU0200804A patent/HU229263B1/hu not_active IP Right Cessation
- 2000-01-18 ID IDW00200101696A patent/ID30180A/id unknown
- 2000-01-18 PL PL350735A patent/PL197693B1/pl not_active IP Right Cessation
- 2000-01-18 RS YU54401A patent/RS50242B/sr unknown
- 2000-01-18 EA EA200100742A patent/EA004786B1/ru not_active IP Right Cessation
- 2000-01-18 SK SK1086-2001A patent/SK286747B6/sk not_active IP Right Cessation
- 2000-01-18 EP EP00909918A patent/EP1150746B1/en not_active Expired - Lifetime
- 2000-01-18 IL IL14466800A patent/IL144668A/xx not_active IP Right Cessation
- 2000-01-18 AU AU32098/00A patent/AU777368B2/en not_active Ceased
- 2000-01-18 SI SI200030517T patent/SI1150746T1/xx unknown
- 2000-01-18 ME MEP-105/08A patent/MEP10508A/xx unknown
- 2000-01-18 BR BR0007911-1A patent/BR0007911A/pt not_active Application Discontinuation
- 2000-01-18 DE DE60013555T patent/DE60013555T2/de not_active Expired - Lifetime
- 2000-01-18 CZ CZ20012804A patent/CZ300395B6/cs not_active IP Right Cessation
- 2000-01-18 KR KR1020017009716A patent/KR100793047B1/ko not_active IP Right Cessation
- 2000-01-18 ES ES00909918T patent/ES2226792T3/es not_active Expired - Lifetime
- 2000-01-18 NZ NZ512822A patent/NZ512822A/en not_active IP Right Cessation
- 2000-01-18 AP APAP/P/2001/002218A patent/AP1469A/en active
- 2000-01-18 PT PT00909918T patent/PT1150746E/pt unknown
- 2000-01-25 TW TW089101215A patent/TWI273907B/zh not_active IP Right Cessation
- 2000-02-01 AR ARP000100420A patent/AR042569A1/es not_active Application Discontinuation
-
2001
- 2001-07-05 NO NO20013335A patent/NO330512B1/no not_active IP Right Cessation
- 2001-07-06 ZA ZA200105596A patent/ZA200105596B/en unknown
- 2001-07-11 HR HR20010521A patent/HRP20010521A2/hr not_active Application Discontinuation
- 2001-07-27 BG BG105751A patent/BG65151B1/bg unknown
- 2001-08-23 CR CR6448A patent/CR6448A/es not_active Application Discontinuation
-
2002
- 2002-05-31 HK HK02104062.3A patent/HK1042445B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU54401A (sh) | Primena derivata 4-h-1-benzopiran-4-ona kao inhibitora preteranog razmnožavanja ćelija glatkih mišića | |
Schuppan et al. | Hepatic fibrosis: from bench to bedside | |
Lester et al. | Effect of pyrazoles and other compounds on alcohol metabolism | |
NO20063373L (no) | CD40-antistoff-formuleringer og fremgangsmater | |
BRPI0408999A (pt) | comprimidos prensados de multiparticulados de liberação oral prolongada | |
ATE340581T1 (de) | Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe | |
ATE485825T1 (de) | Therapeutische inhibitoren der zellen der glatten gefässmuskulatur | |
NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
GEP20022786B (en) | Purine Inhibitors of Cyclin Dependent Kinase 2 and 1kB-a | |
CA2212537A1 (en) | Therapeutic inhibitor of vascular smooth muscle cells | |
NO20053077L (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
GEP20053511B (en) | ) β-Carboline Derivatives Useful as Inhibitors of Phosphodiesterase | |
NO20026171L (no) | Topiske farmasöytiske formuleringer og fremgangsmåter for behandling | |
WO2004110302A3 (en) | Methods of delivering anti-restenotic agents from a stent | |
JP2002522485A5 (sh) | ||
DE602004032149D1 (de) | Oros-push-stick für die kontrollierte abgabe von wirkstoffen | |
AR026197A1 (es) | Uso de dipiridamol o mopidamol para el tratamiento y prevencion de trastornos de la microcirculacion dependientes de fibrina | |
CA2368165C (en) | Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases | |
Jagetia et al. | Ascorbic acid increases healing of excision wounds of mice whole body exposed to different doses of γ-radiation | |
BR0008443A (pt) | Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética | |
DE60313356D1 (de) | Verwendungvon dextransulfat zur behandlung von ibmir | |
ATE298256T1 (de) | Biomaterial in form von mikropartikeln von hyaluronsaure zur medizinischen verwendung | |
HK1046094A1 (en) | Ppar delta inhibitors for the treatment of cardiovascular diseases | |
HUP0203486A2 (hu) | Véralvadással összefüggő betegségek megelőzése és kezelése | |
Chang et al. | Differential contributions of nitric oxide synthase isoforms at hippocampal formation to negative feedback regulation of penile erection in the rat |